Read the full paper: CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy

BNT211 hat das Potential, die erste Therapie dieser Art zu werden, indem der Kandidat zwei innovative Ansätze kombiniert: eine autologe CAR-T-Zelltherapie mit dem onkofetalen Antigen Claudin-6 (CLDN6...

Verismo Therapeutics has broadened its KIR-CAR approach by introducing a new therapy targeting Claudin 6, enhancing treatment options for solid tumors alongside mesothelin targeting.

BNT211 hat das Potential, die erste Therapie dieser Art zu werden, indem der Kandidat zwei innovative Ansätze kombiniert: eine autologe CAR-T-Zelltherapie mit dem onkofetalen Antigen Claudin-6 (CLDN6...

TORL BioTherapeutics, led by ex-Celgene CEO Mark Alles, raises $96M for CLDN6 trial. Company's ADC TORL-1-23 in Phase 2 for ovarian cancer, with data expected 2027.

Axcynsis Therapeutics has received FDA clearance for AT03-65, an ADC targeting CLDN6-positive tumors, enabling a new clinical trial. This marks a significant innovation in cancer therapy.

Context Therapeutics (Nasdaq:CNTX) reported positive interim Phase 1a data for CTIM-76, a CLDN6 x CD3 T cell engager, in advanced platinum-resistant ovarian cancer (PROC).Among efficacy-evaluable PROC patients at active doses, ORR was 29%, DCR 57%, with ≥6-month disease control in three patients and predominantly low-grade, reversible adverse events. CTIM-76 has FDA Fast Track in PROC, and PK supports Q3W dosing starting 2H 2026.

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million

Context Therapeutics (Nasdaq: CNTX) announced that the FDA granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for treatment of platinum-resistant ovarian cancer (PROC).CTIM-76 is in a Phase 1 trial evaluating safety, tolerability, pharmacokinetics and anti-tumor activity in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The company expects interim Phase 1a data in June 2026.

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA,

Context Therapeutics (Nasdaq: CNTX) reported third-quarter 2025 results and a clinical update on its T cell engager pipeline. As of September 30, 2025, cash and cash equivalents were $76.9 million and the company expects runway into 2027. The company reported a Q3 2025 net loss of $9.7 million versus $17.5 million in Q3 2024 and R&D expense of $8.7 million versus $16.8 million a year earlier, driven largely by lower CT-202 and CT-95 spend.Clinical highlights: CTIM-76 (CLDN6 x CD3) has enrolled 12 patients (cutoff Oct 30, 2025), shows preliminary RECIST responses beginning in Cohort 3, no CRS > Grade 1, no DLT, and MTD not reached; updated Phase 1a/Phase 1b dose selection expected Q2 2026. CT-95 (MSLN x CD3) has enrolled 6 patients, is in Cohort 3 with target exposure projected at Cohort 4, no DLT, and no CRS > Grade 2; initial Phase 1a data expected mid-2026. CT-202 remains preclinical with planned filings toward a first-in-human trial in Q2 2026.

Context Therapeutics (CNTX) reported its full year 2024 financial results and business highlights. The company ended 2024 with $94.4 million in cash, expected to fund operations into 2027. Key developments include the first patient dosed with CTIM-76 in January 2025 for CLDN6-positive cancers, acquisition of CT-95, and in-licensing of CT-202.Financial results show R&D expenses increased to $22.7 million in 2024 from $17.8 million in 2023, primarily due to $14.75 million in research charges related to CT-95 acquisition and CT-202 licensing. The company reported a net loss of $26.7 million for 2024, compared to $24.0 million in 2023.Upcoming milestones include first patient dosing for CT-95 in Q2 2025, initial CTIM-76 clinical data in H1 2026, and CT-95 trial data in mid-2026.

First patient dosed in trial evaluating CTIM-76, targeting CLDN6-positive gynecologic and testicular cancers. Study to enroll 70 patients with data expected in H1 2026.

QLS5132 led to a 50% ORR and manageable safety in PROC, supporting CLDN6 as a promising ADC target in early-phase clinical development.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Claudins are essential components of tight junctions, and their abnormal expression is linked to cancer development. Claudin-6 (CLDN6) and Claudin-9 (CLDN9) are claudins whose expression is suppres...

Claudins are essential components of tight junctions, and their abnormal expression is linked to cancer development. Claudin-6 (CLDN6) and Claudin-9 (CLDN9) are claudins whose expression is suppres...

Secured $96M Series C Financing; Total Raised Since 2019 Founding Exceeds $450M Proceeds Fund the Clinical Development of TORL-1-23, Currently in a Registrational Phase 2 Study for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer and in Phase 1 for other CLDN6+ Cancers...

-- ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability, pharmacokinetics and antitumor activity of ARC101 in patients…

PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, has been dosed in the first patient…

Profit on the stock market by investing in biotech stocks